Jazz Pharmaceuticals Plc SEC Filings

Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc (JAZZ), reported two open-market sales under a Rule 10b5-1 trading plan. On 10/01/2025 he sold 2,000 ordinary shares at $131.78, reducing his beneficial holdings to 412,326 shares. On 10/03/2025 he sold an additional 3,500 shares at $140.00, reducing holdings to 408,826 shares. The Form 4 is signed by an attorney-in-fact and notes the transactions were executed pursuant to the disclosed 10b5-1 plan.

Jazz Pharmaceuticals plc insider filing reports a proposed sale of 3,500 common shares to be executed on or about 10/03/2025 through Merrill Lynch on Nasdaq, with an aggregate market value of $490,000. The filing shows those shares were originally acquired as executive compensation on 10/04/2021 and 11/01/2021 (totaling 3,500 shares). The filer, identified as Bruce C Cozadd in prior sales records, disclosed three prior sales in the past three months totaling 9,000 shares for combined gross proceeds of $1,148,460 (sales on 08/01/2025, 09/02/2025, and 10/01/2025). The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.

Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc (JAZZ), reported a transaction on 09/14/2025. The Form 4 shows 15,647 ordinary shares were disposed under code F(1) at a price of $126.16 per share. The filing explains the shares were withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units.

After the withholding, Mr. Cozadd beneficially owns 414,326 ordinary shares (reported as direct ownership). The Form 4 was signed on 09/17/2025 by an attorney-in-fact, and the reporting person is identified with an address in Dublin and relationship as Director.

Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc (JAZZ), reported two open-market sales executed under a Rule 10b5-1 trading plan on 09/02/2025. The filings show sales of 3,000 ordinary shares at $127.23 (leaving 432,973 shares beneficially owned) and 3,000 ordinary shares at $130.00 (leaving 429,973 shares beneficially owned) after each reported transaction. The report was signed by an attorney-in-fact on behalf of Mr. Cozadd on 09/04/2025 and includes a statement that the transactions were effected pursuant to a Rule 10b5-1 trading plan.

Kenneth W. O'Keefe, identified as a director of Jazz Pharmaceuticals (JAZZ), reported both a grant of restricted stock units and a sale of ordinary shares. On 08/07/2025 he was granted 3,507 restricted stock units under the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan; each unit represents a contingent right to one ordinary share and, subject to continuous service and conditions, vests in full on July 24, 2026. The next day, 08/08/2025, he sold 1,805 shares at $111.2502 per share to satisfy tax obligations arising from the vesting of previously granted restricted stock units. Following these transactions the reporting person beneficially owns 28,672 shares directly, and 4,445 shares indirectly through The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, of which he is trustee and beneficiary.

Jennifer E. Cook, a director of Jazz Pharmaceuticals (JAZZ), reported equity activity involving restricted stock units and a share sale on Form 4. The filing shows a grant of 3,507 restricted stock units under the company's director award plan; each unit represents a contingent right to one ordinary share and the units vest in full on July 24, 2026 subject to continuous service and plan conditions. Following that grant the reported beneficial ownership rose to 12,642 ordinary shares.

The filing also discloses a sale of 1,805 shares at a price of $111.2494 described as shares sold to satisfy tax obligations arising from vesting of previously granted restricted stock units, leaving 10,837 shares beneficially owned by the reporting person after the sale.

Patrick Enright, identified as a director of Jazz Pharmaceuticals (JAZZ), was granted 3,507 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one ordinary share and, subject to continued service and other conditions, the units will vest in full on July 24, 2026. The filing also reports a sale of 1,805 ordinary shares on 08/08/2025 at $111.2491 to satisfy tax obligations arising from the vesting of previously granted RSUs. The reported direct beneficial ownership rose to 28,184 shares following the RSU grant and declined to 26,379 shares after the tax-related sale.

Laura Hamill, a director of Jazz Pharmaceuticals (JAZZ), reported two related transactions. On 08/07/2025 she was granted 3,507 restricted stock units under the issuer's non-employee directors stock award plan; each unit represents a contingent right to one ordinary share and the units are scheduled to vest in full on July 24, 2026, subject to continued service and plan conditions. On 08/08/2025 she sold 1,805 shares to satisfy tax obligations arising from prior RSU vesting at a reported price of $111.2502 per share. Reported beneficial ownership was 8,738 shares after the grant and 6,933 shares after the sale. These filings reflect routine director compensation and a sell-to-cover tax transaction.

Patrick Kennedy, a director of Jazz Pharmaceuticals (JAZZ), received a grant of 3,507 restricted stock units under the issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to one ordinary share upon vesting; the units will vest in full on July 24, 2026 subject to the reporting person's continuous service and additional conditions.

Following the grant activity, the reporting person sold 1,959 shares at $111.2506 per share to satisfy tax obligations arising from the vesting of previously granted restricted stock units, which reduced beneficial ownership from 8,661 shares to 6,702 shares.